LAUSR

Dear Editor, We read with interest the article by Bajric and Bakri. The authors evaluated the outcomes of visual acuity (VA) and central retinal thickness (CRT) in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) who were initially treated with intravitreal bevacizumab (IVB; Avastin, Genentech Inc., South San Francisco, CA) and followed for up to four years. This observational case series included 51 patients with non-ischemic and ischemic CRVOs. The mean number of IVB injections per patient was 5.9 in the first year and then declined throughout years two, three, and four to 2.6, 2.8, and 2.2, respectively. Mean VA improved from 20/214 at baseline to 20/107 at one year and increased to 20/69 at four years. CRT decreased from 595 μm at baseline to 339 μm at one year and increased to 427 μm at four years. The authors concluded that patients who received IVB as initial therapy for ME from CRVO maintained VA and CRT improvement for up to four years. The study is clinically relevant because it shows how patients are treated in the real world. However, the study has several limitations, which partially prevent the validation of their results and which can be summarized as follows: